NervGen Pharma Corp.
NGENF
Price:
$4.25
Market Cap:
$458.32M
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
Industry
Biotechnology
IPO Date
2019-04-03
Stock Exchange
OTC
Ticker
NGENF
PE Ratio
[-16.35]
ROE
[-879.68%]
Current Ratio
[0.92]
Dividend Yield
[0%]
Enterprise Value
[442.70M]
Dividend History
The ROE as of December 2025 (TTM) for NervGen Pharma Corp. (NGENF) is -879.68%
According to NervGen Pharma Corp.’s latest financial reports and current stock price. The company's current ROE is -879.68%. This represents a change of -1213.19% compared to the average of 79.02% of the last 4 quarters.
NervGen Pharma Corp. (NGENF) Historical ROE (quarterly & annually)
How has NGENF ROE performed in the past?
The mean historical ROE of NervGen Pharma Corp. over the last ten years is -41.95%. The current -879.68% ROE has changed 2.00% with respect to the historical average. Over the past ten years (40 quarters), NGENF's ROE was at its highest in in the June 2025 quarter at 991.29%. The ROE was at its lowest in in the December 2024 quarter at -334.11%.
Average
-41.95%
Median
-104.84%
Minimum
-931.69%
Maximum
1.11%
NervGen Pharma Corp. (NGENF) ROE by Quarter and Year
Discovering the peaks and valleys of NervGen Pharma Corp. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 206.28%
Maximum Annual ROE = 1.11%
Minimum Annual Increase = -928.22%
Minimum Annual ROE = -931.69%
| Year | ROE | Change |
|---|---|---|
| 2024 | -931.69% | -183.63% |
| 2023 | 1.11% | -928.22% |
| 2022 | -134.51% | 78.94% |
| 2021 | -75.17% | -60.18% |
| 2020 | -188.78% | 14.08% |
| 2019 | -165.48% | 206.28% |
| 2018 | -54.03% | -154.03% |
NervGen Pharma Corp. (NGENF) Average ROE
How has NGENF ROE performed in the past?
The current ROE of NervGen Pharma Corp. (NGENF) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
15.95%
5-year avg
-43.22%
10-year avg
-41.95%
NervGen Pharma Corp. (NGENF) ROE vs. Peers
How is NGENF’s ROE compared to its peers?
NervGen Pharma Corp.’s ROE is greater than JW (Cayman) Therapeutics Co. Ltd (-59.45%), greater than Brii Biosciences Limited (-14.61%), greater than Genfit S.A. (-63.70%), less than Scancell Holdings plc (126.94%), greater than Molecular Partners AG (-50.31%), greater than NDT Pharmaceuticals Inc. (-20.34%), greater than Botanix Pharmaceuticals Limited (-99.43%), greater than Innate Pharma S.A. (-658.91%), greater than Santhera Pharmaceuticals Holding AG (-521.53%), less than BICO Group AB (publ) (-7.46%),
| Company | ROE | Market cap |
|---|---|---|
| -59.45% | $150.63M | |
| -14.61% | $173.42M | |
| -63.70% | $206.16M | |
| 126.94% | $140.10M | |
| -50.31% | $134.64M | |
| -20.34% | $158.40M | |
| -99.43% | $150.41M | |
| -658.91% | $183.43M | |
| -521.53% | $172.71M | |
| -7.46% | $152.60M |
Build a custom stock screener for NervGen Pharma Corp. (NGENF) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NervGen Pharma Corp. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
NervGen Pharma Corp. (NGENF) and other stocks custom spreadsheet templates
The easiest way to analyze a company like NervGen Pharma Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is NervGen Pharma Corp.'s ROE?
How is the ROE calculated for NervGen Pharma Corp. (NGENF)?
What is the highest ROE for NervGen Pharma Corp. (NGENF)?
What is the 3-year average ROE for NervGen Pharma Corp. (NGENF)?
What is the 5-year average ROE for NervGen Pharma Corp. (NGENF)?
How does the current ROE for NervGen Pharma Corp. (NGENF) compare to its historical average?